SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to recent revenue growth and speculation around a potential crypto treasury strategy, sparking significant after-hours volatility. The community is actively debating the stock's low float and potential for a short squeeze, with some cautioning against chasing the spike. Discussions also include the company's compliance status and potential catalysts for further upward movement.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recently announced $5 million production order and a $150 million registered direct offering, signaling strong institutional investor confidence. The community is actively discussing the implications of these developments for POET's growth in the AI infrastructure market and its potential to scale production. Discussions include comparing POET to other companies and analyzing the significance of partnerships with major industry players in photonics.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending as investors react to news of Larvotto Resources rejecting its acquisition offer, with community discussions focusing on the deal's potential restructuring and the company's intrinsic value. Despite the setback, many express confidence in UAMY's fundamentals, citing existing contracts and potential government support amid increasing geopolitical tensions around critical mineral supply chains. The community is weighing the short-term bearish sentiment against the long-term potential of UAMY in the antimony market.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as the community reminisces about the stock's past volatility and discusses potential short squeezes, drawing comparisons to other meme stocks like $BYND. A recent White House post using GameStop's slogan has further fueled the conversation and speculative interest. Traders are actively debating potential price movements and the influence of market makers.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, potential rate cuts, and possible S&P 500 inclusion. The community is bullish, fueled by optimism around growth prospects, crypto offerings, and increasing membership. Many see a breakout above the $30 resistance level and are discussing potential price movements post-earnings.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending following news of a potential acquisition by Novartis, with the deal speculated to strengthen Novartis's neuroscience pipeline. The community is buzzing about the potential buyout price, the value of the spin-off company, and the implications for the broader RNA therapeutics sector. Some traders point to options activity as a signal and congratulate long-term holders.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending as investors discuss its potential acquisition by INCY and compare it to competitor KURA, particularly focusing on the safety profiles of their respective leukemia treatments. Community members are weighing the impact of a recent FDA approval for Syndax's Revuforj against concerns over a "black box" warning, while also evaluating future revenue potential and possible buyout scenarios.

Banco BBVA Argentina SA engages in the provision of banking and financial services. It operates through the following business lines: retail banking; small and medium-sized companies; and corporate and investment banking (CIB). The retail banking business includes checking and savings accounts, time deposits, credit cards, personal and auto loans, mortgages, insurance, and investment products. The small and medium-sized companies business focuses on local private-sector companies. The CIB business covers global transaction services and global markets solutions such as risk management and securities brokerage, long term financing products as well as project finance and syndicated loans, and corporate finance services. The company was founded on October 14, 1886 and is headquartered in Buenos Aires, Argentina.

BBVA Argentina - ADR

Banco Bbva Argentina SA

BBAR is trending as investors monitor Argentinian equities following recent political developments, with some anticipating a potential rally due to a shift in leadership. Community members are actively discussing the stock's potential for significant gains, while acknowledging the inherent volatility and risks associated with the Argentinian market. The stock's low P/E ratio and the potential for increased foreign investment are also key discussion points.

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

Doximity Inc - Ordinary Shares - Class A

Doximity Inc

Doximity is trending following a mix of analyst ratings, including upgrades from Bank of America and Baird, contrasted by downgrades from JP Morgan and Goldman Sachs, leading to community debate around valuation and growth prospects. Community members are actively discussing the potential impact of FDA regulations on pharmaceutical advertising, with some highlighting the company's AI initiatives and strong cash position, while others express concerns about slowing growth. Option traders are closely watching unusual options activity, with both bullish and bearish sentiment observed, and a focus on call options expiring in 2026.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community anticipates its listing on Kraken, with discussions focusing on potential price movements and the long-term vision of the project. Some community members are drawing comparisons to XRP and highlighting Zebec's partnerships and regulatory compliance, while others express skepticism and caution against unrealistic expectations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Futures Rise As Global Debasement Trade Sends Gold Over $4000

Futures Rise As Global Debasement Trade Sends Gold Over $4000 Futures are higher again, reversing Tuesday's modest Oracle-led decline, and are led by small caps despite additional multi billion tech...

H.C. Wainwright on Monday set a price target of $11 for CervoMed (CRVO) shares while keeping a ‘Neutral’ rating. The target implies a premium of nearly 5% from the stock’s closing price on Friday.The regulatory outlook for Neflamapimod should be clarified in the near term, the analyst told investors in a research note. The firm noted CervoMed is actively preparing for discussions with the U.S. Food and Drug Administration (FDA), which management expects to take place during the fourth quarter.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRVO">CervoMed</a> trended in the ‘extremely bullish’ territory, while message volume is at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_12_48_27_PM_png_0e348d0430.webp" alt="CRVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>CRVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>Late in July, Cervomed <a href="https://stocktwits.com/news-articles/markets/equity/cervomed-dementia-drug-slows-disease-progression-in-study/choeuj6R5xa">said</a> that Neflamapimod continued to slow disease progression in a type of dementia during the extension phase of its mid-stage trial. Dementia with Lewy Bodies (DLB) patients treated with Neflamapimod showed a 54% risk reduction in clinically significant worsening at week 32 of treatment, the company said.DLB is a type of dementia characterized by the presence of Lewy bodies, which are protein clumps, in the brain. It is the second most common form of neurodegenerative dementia, following Alzheimer's disease.The company then also confirmed that it is looking forward to initiating late-stage trials and is preparing to meet with the U.S. Food and Drug Administration in the fourth quarter to align on the trial design.In the second quarter of 2025, CervoMed also enrolled the first patients in a mid-stage trial of Neflamapimod in patients recovering from acute stroke. It also initiated a mid-stage trial of Neflamapimod in patients with the nonfluent/agrammatic variant of primary progressive aphasia (PPA) – a subtype of frontotemporal dementia (FTD).Neflamapimod was granted Orphan Drug designation for the treatment of FTD in November 2024. Frontotemporal dementia (FTD) is a group of brain disorders characterized by the progressive degeneration of the brain's frontal and temporal lobes, leading to changes in personality, behavior, and language.According to data from Koyfin, all six analysts covering CervoMed rate it a ‘Buy’. The stock has an average price target of $21.50.CRVO stock is up 334% this year but down approximately 36% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-stock-slips-after-us-regulator-probes-287000-chrysler-minivans/chwhGZoRdrX">Stellantis Stock Slips After US Regulator Probes 287,000 Chrysler Minivans Over Concerns Regarding Electric Power Steer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear Soon

H.C. Wainwright’s price target implies a premium of nearly 5% from the stock’s closing price on Friday.

CervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear Soon 

Equity

H.C. Wainwright’s price target implies a premium of nearly 5% from the stock’s closing price on Friday.


Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +100.00% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of +1,166.67% and +14.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

CervoMed Inc. (CRVO) announced on Monday that its drug continued to slow disease progression in a type of dementia during the extension phase of its mid-stage trial.Dementia with Lewy Bodies (DLB) patients treated with Neflamapimod showed a 54% risk reduction in clinically significant worsening compared to control at week 32 of treatment based on Clinical Dementia Rating Sum of Boxes, a standard measure of clinical progression in dementia trials, the company said. &nbsp;The risk reduction improved to 64% among patients with minimal Alzheimer’s disease co-pathology, it added.DLB is a type of dementia characterized by the presence of Lewy bodies, which are clumps of protein, in the brain. It is the second most common form of neurodegenerative dementia, following Alzheimer's disease.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRVO">CervoMed</a> trended in the ‘extremely bullish’ territory, while message volume is at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_28_at_12_07_40_PM_png_3051704308.webp" alt="CRVO's Sentiment Meter and Message Volume as of 12:05 p.m. ET on July 28, 2025 | Source: Stocktwits" width="626" height="60"><figcaption>CRVO's Sentiment Meter and Message Volume as of 12:05 p.m. ET on July 28, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user indicated they are awaiting analysts’ takes on the news.<stembedurl>https://stocktwits.com/generaltom/message/622721810</stembedurl>Another user praised the result and highlighted that they have loaded up on the stock.<stembedurl>https://stocktwits.com/roquefort/message/622678785</stembedurl>Lawrence S. Honig, Professor of Neurology at Columbia University Irving Medical Center, stated that this level of effect, if confirmed in a Phase 3 pivotal trial, would be an important advance in the unmet treatment needs of patients with DLB, the second most common dementia.The company is now looking forward to initiating late-stage trials and is preparing to meet with the U.S. Food and Drug Administration in the fourth quarter to align on the trial design.The firm also said that at week 32 of the extension phase, there was a statistically significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP).Plasma levels of glial fibrillary acidic protein (GFAP) are generally low in healthy individuals but can increase with certain neurological conditions.No new safety signals were identified during the extension phase of the trial, it added.CRVO stock is up by over 300% this year but down by 33% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/graphjet-ceo-says-company-expects-to-benefit-from-16.5-billion-tesla-samsung-deal/choes4fR5x3">Graphjet Stock Rockets 36% After CEO Says Company Expects To Benefit From $16.5B Tesla-Samsung Deal: Retail Wants To Buy More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of female hand touching stock market analysis digital display screen TradingView chart, analyzing investment and financial trading data in candlestick chart on a touch screen interface.

CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock

The company is now poised to initiate late-stage trials for Neflamapimod. 

CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?

CERVOMED INC (CRVO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Shares of CervoMed Inc. (<a class="mention" data-mention="$CRVO" data-symbol-id="CRVO" href="https://stocktwits.com/symbol/CRVO" target="_blank">$CRVO</a>) jumped more than 12% in pre-market trading on Wednesday, on course to snap a two-day losing streak, and grabbed retail attention.The company announced that its oral investigational drug, neflamapimod, was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of frontotemporal dementia (FTD).Neflamapimod, currently undergoing a Phase 2b study in patients with early-stage dementia with Lewy bodies (DLB), is showing promise in targeting specific pathogenic mechanisms associated with FTD.&nbsp;The designation recognizes the drug’s potential to address a rare condition affecting approximately 50,000 to 60,000 people in the U.S., with a higher prevalence in Europe and potentially in Asia and Latin America.John Alam, CEO of CervoMed, highlighted the significance of this milestone, noting that the company is actively working with clinical experts to design a proof-of-principle study for FTD while preparing to move neflamapimod into a Phase 3 trial for DLB in mid-2025.&nbsp;The Orphan Drug status provides CervoMed with several key benefits, including tax credits for clinical trial costs, regulatory assistance, and seven years of post-approval market exclusivity.Analyst Jason Kolbert from D. Boral Capital maintained a ‘Buy’ rating on the stock, setting a price target of $34, which implies over four times upside from the stock’s previous close.<figure class="image"><a href="https://stocktwits.com/symbol/CRVO"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CRVO_sentiment_and_message_volume_Nov_27_premarket_7ed58203f3.png" alt="CRVO sentiment and message volume Nov 27 premarket.png" width="1318" height="318"></a><figcaption>CRVO sentiment and message volume Nov 27 premarket as of 9:15 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, the sentiment surrounding CervoMed shifted dramatically from ‘bearish’ to ‘extremely bullish,’ with a surge in message volume reflecting renewed optimism among retail investors.&nbsp;<stembedurl>https://stocktwits.com/ajmore/message/594262803</stembedurl><stembedurl>https://stocktwits.com/AnalRetort/message/594262019</stembedurl>While CervoMed’s stock has dipped 0.25% year-to-date, the latest news has reignited investor interest, propelling the stock to among the top 15 trending symbols before the bell on Wednesday.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amgn-stock-slips-premarket-after-rbc-cuts-price-target/cJI0wiDRW7">Amgen Stock Slips After More Analyst Criticism On Weight-Loss Drug Data: Retail Eyes ‘Great Buying Opportunity’</a>

Neflamapimod, currently undergoing a Phase 2b study in patients with early-stage dementia with Lewy bodies (DLB)

CervoMed Stock Surges On FDA Orphan Drug Nod For FTD Treatment: Retail Optimism Rekindled

The Orphan Drug status provides CervoMed with several key benefits, including tax credits for clinical trial costs, regulatory assistance, and seven years of post-approval market exclusivity.

Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now

MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The...

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. CervoMed, Inc. was founded in1995 and is headquartered in Boston, MA.

CervoMed Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

CRVO
CervoMed Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRVO News

CRVOCervoMed Inc